SS Innovations — Surgical Robotics Scaling Fast Outside the U.S.

SS Innovations is quietly becoming one of the more interesting emerging names in surgical robotics.

The company’s Q1 2026 results showed:

• Q1 2026 revenue: $11.1M, up 116.8% YoY

• Gross margin: 48.0%

• Net loss: $3.6M, improved from $5.7M

• Q1 installations: 26

• Installed base: 194 systems across 11 countries

• Cumulative surgeries: 9,744, including 157 telesurgeries

• Cash: $16.0M

• Long-term debt: $0

The bigger story may be where the growth is happening.

Unlike many robotic surgery companies targeting premium Western hospitals first, SS Innovations is aggressively focused on:

• India

• Southeast Asia

• Middle East

• Africa

• Cost-sensitive healthcare systems globally

Its thesis is straightforward:

Robotic surgery should be dramatically cheaper and more accessible.

The company claims its SSi Mantra platform can reduce the cost barrier versus incumbent systems while still supporting complex procedures including:

• Cardiac surgery

• Bariatric surgery

• Gynecology

• Urology

• Pediatric surgery

Telesurgery

SS Innovations recently received telesurgery approvals in Indonesia and the Philippines and has now completed more than 150 remote robotic surgeries.

The company also highlighted:

• 18 inter-hospital telesurgeries completed in a single day

• Continued international regulatory approvals

• Potential FDA review milestones in 2026

• Ongoing preparation for U.S. and EU expansion